The Experts below are selected from a list of 1416 Experts worldwide ranked by ideXlab platform
Elizabeth Miller - One of the best experts on this subject based on the ideXlab platform.
-
antibody persistence in uk pre school children following primary series with an acellular pertussis containing pentavalent Vaccine given concomitantly with meningococcal group c conjugate Vaccine and response to a booster dose of an acellular pertussis containing quadrivalent Vaccine
Vaccine, 2009Co-Authors: Nicholas Kitchin, Joanna Southern, Rhonwen Morris, Ray Borrow, Anne Fiquet, Florence Boisnard, Stephane Thomas, Elizabeth MillerAbstract:Abstract This open-label, randomised, controlled study examined antibody persistence following infant vaccination at 2, 3 and 4 months of age with either an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Haemophilus influenzae type b (DT 5 aP-IPV-Hib; Pediacel ® ) or a whole-cell pertussis (DTwP//Hib + Oral Poliomyelitis Vaccine [OPV]) combination Vaccine, given concomitantly with meningococcal serogroup C conjugate (MCC) Vaccine, followed by a Hib booster at approximately 15 months of age. Immune responses were sustained to 3.5–4.5 years of age for all antigens contained in Pediacel. Administration of an acellular pertussis-containing quadrivalent pre-school booster (Td 5 ap-IPV; Repevax ® ), with or without measles, mumps and rubella (M-M-R™II) Vaccine, induced robust antibody responses indicative of protection, regardless of the Vaccine used for the primary series. Reactogenicity of Repevax was acceptable and consistent with previous experience.
-
a randomised controlled study of the reactogenicity of an acellular pertussis containing pentavalent infant Vaccine compared to a quadrivalent whole cell pertussis containing Vaccine and Oral Poliomyelitis Vaccine when given concurrently with meningococcal group c conjugate Vaccine to healthy uk infants at 2 3 and 4 months of age
Vaccine, 2006Co-Authors: Nicholas Kitchin, Joanna Southern, Rhonwen Morris, Fabienne Hemme, Keith Cartwright, Michael Watson, Elizabeth MillerAbstract:Two hundred forty-one healthy infants were enrolled in an open randomised controlled study of three doses of DTaP-IPV-Hib (Group 1) or DTwP/Hib+OPV (Group 2) at 2, 3 and 4 months of age given concurrently with a meningitis C conjugate Vaccine. After each dose, local reactions (any grade) were less common in Group 1 than Group 2 (p 37.5 degrees C, decreased feeding, reduced activity, irritability and crying in the week after vaccination were also less common in Group 1 than Group 2 (p<0.05 for each symptom, all doses combined). Severe local reactions and systemic symptoms were uncommon and occurred equally in both groups. The pentavalent DTaP-IPV-Hib Vaccine was less reactogenic than the quadrivalent DTwP-Hib Vaccine, as expected when changing from whole cell pertussis (wP) to an acellular pertussis (aP) component.
Eliete Da Cunha Araujo - One of the best experts on this subject based on the ideXlab platform.
-
seguranca imunogenicidade e eficacia protetora de duas doses da vacina rix4414 contendo rotavirus atenuado de origem humana
Jornal De Pediatria, 2007Co-Authors: Eliete Da Cunha Araujo, Consuelo Silva De Oliveira, Pilar Rubio, Yvone Benchimol Gabbay, Veronilce B Da Silva, Sue Ann Costa Clemens, Maria Cleonice Aguiar Justino, Joana Darc Pereira Mascarenhas, Vânia Lucia Noronha, Ralf ClemensAbstract:OBJECTIVE: To determine the safety, immunogenicity and efficacy of two doses of rotavirus Vaccine in healthy Brazilian infants. METHODS: A randomized, multicenter, double-blind, placebo-controlled trial was conducted in Brazil, Mexico and Venezuela. Infants received two Oral doses of Vaccine or placebo at 2 and 4 months of age, concurrently with routine immunizations, except for Oral Poliomyelitis Vaccine (OPV). This paper reports results from Belem, Brazil, where the number of subjects per group and the viral Vaccine titers were: 194 (104.7 focus forming units - FFU), 196 (105.2 FFU), 194 (105.8 FFU) and 194 (placebo). Anti-rotavirus (anti-RV) antibody response was assessed in 307 subjects. Clinical severity of gastroenteritis episodes was measured using a 20-point scoring system with a score of > 11 defined as severe GE. RESULTS: The rates of solicited general symptoms were similar in Vaccine and placebo recipients. At 2 months after the second dose, a serum IgA response to RV occurred in 54.7 to 74.4% of Vaccinees. No interference was seen in the immunogenicity of routine Vaccines. Vaccine efficacy against any rotavirus gastroenteritis (RVGE) was 63.5% (95%CI 20.8-84.4) for the highest concentration (105.8 FFU). Efficacy was 81.5% (95%CI 44.5-95.4) against severe RVGE. At its highest concentration (105.8 FFU), RIX4414 provided 79.8% (95%CI 26.4-96.3) protection against severe RVGE by G9 strain. CONCLUSIONS: RIX4414 was highly immunogenic with a low reactogenicity profile and did not interfere with seroresponse to diptheria, tetanus, pertussis, hepatitis B and Hib antigens. Two doses of RIX4414 provided significant protection against severe GE caused by RV.
-
safety immunogenicity and protective efficacy of two doses of rix4414 live attenuated human rotavirus Vaccine in healthy infants
Jornal De Pediatria, 2007Co-Authors: Eliete Da Cunha Araujo, Consuelo Silva De Oliveira, Pilar Rubio, Yvone Benchimol Gabbay, Veronilce B Da Silva, Sue Ann Costa Clemens, Maria Cleonice Aguiar Justino, Joana Darc Pereira Mascarenhas, Vânia Lucia Noronha, Ralf ClemensAbstract:Objective: To determine the safety, immunogenicity and efficacy of two doses of rotavirus Vaccine in healthy Brazilian infants. Methods: A randomized, multicenter, double-blind, placebo-controlled trial was conducted in Brazil, Mexico and Venezuela. Infants received two Oral doses of Vaccine or placebo at 2 and 4 months of age, concurrently with routine immunizations, except for Oral Poliomyelitis Vaccine (OPV). This paper reports results from Belem, Brazil, where the numberofsubjectspergroupandtheviralVaccinetiterswere:194(104.7focusformingunits–FFU),196(105.2FFU),194 (10 5.8 FFU) and 194 (placebo). Anti-rotavirus (anti-RV) antibody response was assessed in 307 subjects. Clinical severity of gastroenteritis episodes was measured using a 20-point scoring system with a score of ≥ 11 defined as severe GE. Results:TheratesofsolicitedgeneralsymptomsweresimilarinVaccineandplaceborecipients.At2monthsafterthe second dose, a serum IgA response to RV occurred in 54.7 to 74.4% of Vaccinees. No interference was seen in the immunogenicity of routine Vaccines. Vaccine efficacy against any rotavirus gastroenteritis (RVGE) was 63.5% (95%CI 20.8-84.4) for the highest concentration (10 5.8 FFU). Efficacy was 81.5% (95%CI 44.5-95.4) against severe RVGE. At its highest concentration (105.8 FFU), RIX4414 provided 79.8% (95%CI 26.4-96.3) protection against severe RVGE by G9 strain. Conclusions: RIX4414 was highly immunogenic with a low reactogenicity profile and did not interfere with seroresponse to diptheria, tetanus, pertussis, hepatitis B and Hib antigens. Two doses of RIX4414 provided significant protection against severe GE caused by RV.
-
safety immunogenicity and protective efficacy of two doses of rix4414 live attenuated human rotavirus Vaccine in healthy brazilian infants seguranca imunogenicidade e eficacia protetora de duas doses da vacina rix4414 contendo rotavirus atenuado de origem humana
2007Co-Authors: Eliete Da Cunha Araujo, Sue Ann, C Clemens, Consuelo Silva De Oliveira, Maria Cleonice, A Justino, Pilar Rubio, Yvone Benchimol Gabbay, Veronilce B Da Silva, Joana Dp MascarenhasAbstract:Objective: To determine the safety, immunogenicity and efficacy of two doses of rotavirus Vaccine in healthy Brazilian infants. Methods: A randomized, multicenter, double-blind, placebocontrolled trial was conducted in Brazil, Mexico and Venezuela. Infants received two Oral doses of Vaccine or placebo at 2 and 4 months of age, concurrently with routine immunizations, except for Oral Poliomyelitis Vaccine (OPV). This paper reports results from Belem, Brazil, where the number of subjects per group and the viral Vaccine titers were: 194 (10 4.7
Ralf Clemens - One of the best experts on this subject based on the ideXlab platform.
-
seguranca imunogenicidade e eficacia protetora de duas doses da vacina rix4414 contendo rotavirus atenuado de origem humana
Jornal De Pediatria, 2007Co-Authors: Eliete Da Cunha Araujo, Consuelo Silva De Oliveira, Pilar Rubio, Yvone Benchimol Gabbay, Veronilce B Da Silva, Sue Ann Costa Clemens, Maria Cleonice Aguiar Justino, Joana Darc Pereira Mascarenhas, Vânia Lucia Noronha, Ralf ClemensAbstract:OBJECTIVE: To determine the safety, immunogenicity and efficacy of two doses of rotavirus Vaccine in healthy Brazilian infants. METHODS: A randomized, multicenter, double-blind, placebo-controlled trial was conducted in Brazil, Mexico and Venezuela. Infants received two Oral doses of Vaccine or placebo at 2 and 4 months of age, concurrently with routine immunizations, except for Oral Poliomyelitis Vaccine (OPV). This paper reports results from Belem, Brazil, where the number of subjects per group and the viral Vaccine titers were: 194 (104.7 focus forming units - FFU), 196 (105.2 FFU), 194 (105.8 FFU) and 194 (placebo). Anti-rotavirus (anti-RV) antibody response was assessed in 307 subjects. Clinical severity of gastroenteritis episodes was measured using a 20-point scoring system with a score of > 11 defined as severe GE. RESULTS: The rates of solicited general symptoms were similar in Vaccine and placebo recipients. At 2 months after the second dose, a serum IgA response to RV occurred in 54.7 to 74.4% of Vaccinees. No interference was seen in the immunogenicity of routine Vaccines. Vaccine efficacy against any rotavirus gastroenteritis (RVGE) was 63.5% (95%CI 20.8-84.4) for the highest concentration (105.8 FFU). Efficacy was 81.5% (95%CI 44.5-95.4) against severe RVGE. At its highest concentration (105.8 FFU), RIX4414 provided 79.8% (95%CI 26.4-96.3) protection against severe RVGE by G9 strain. CONCLUSIONS: RIX4414 was highly immunogenic with a low reactogenicity profile and did not interfere with seroresponse to diptheria, tetanus, pertussis, hepatitis B and Hib antigens. Two doses of RIX4414 provided significant protection against severe GE caused by RV.
-
safety immunogenicity and protective efficacy of two doses of rix4414 live attenuated human rotavirus Vaccine in healthy infants
Jornal De Pediatria, 2007Co-Authors: Eliete Da Cunha Araujo, Consuelo Silva De Oliveira, Pilar Rubio, Yvone Benchimol Gabbay, Veronilce B Da Silva, Sue Ann Costa Clemens, Maria Cleonice Aguiar Justino, Joana Darc Pereira Mascarenhas, Vânia Lucia Noronha, Ralf ClemensAbstract:Objective: To determine the safety, immunogenicity and efficacy of two doses of rotavirus Vaccine in healthy Brazilian infants. Methods: A randomized, multicenter, double-blind, placebo-controlled trial was conducted in Brazil, Mexico and Venezuela. Infants received two Oral doses of Vaccine or placebo at 2 and 4 months of age, concurrently with routine immunizations, except for Oral Poliomyelitis Vaccine (OPV). This paper reports results from Belem, Brazil, where the numberofsubjectspergroupandtheviralVaccinetiterswere:194(104.7focusformingunits–FFU),196(105.2FFU),194 (10 5.8 FFU) and 194 (placebo). Anti-rotavirus (anti-RV) antibody response was assessed in 307 subjects. Clinical severity of gastroenteritis episodes was measured using a 20-point scoring system with a score of ≥ 11 defined as severe GE. Results:TheratesofsolicitedgeneralsymptomsweresimilarinVaccineandplaceborecipients.At2monthsafterthe second dose, a serum IgA response to RV occurred in 54.7 to 74.4% of Vaccinees. No interference was seen in the immunogenicity of routine Vaccines. Vaccine efficacy against any rotavirus gastroenteritis (RVGE) was 63.5% (95%CI 20.8-84.4) for the highest concentration (10 5.8 FFU). Efficacy was 81.5% (95%CI 44.5-95.4) against severe RVGE. At its highest concentration (105.8 FFU), RIX4414 provided 79.8% (95%CI 26.4-96.3) protection against severe RVGE by G9 strain. Conclusions: RIX4414 was highly immunogenic with a low reactogenicity profile and did not interfere with seroresponse to diptheria, tetanus, pertussis, hepatitis B and Hib antigens. Two doses of RIX4414 provided significant protection against severe GE caused by RV.
Nicholas Kitchin - One of the best experts on this subject based on the ideXlab platform.
-
antibody persistence in uk pre school children following primary series with an acellular pertussis containing pentavalent Vaccine given concomitantly with meningococcal group c conjugate Vaccine and response to a booster dose of an acellular pertussis containing quadrivalent Vaccine
Vaccine, 2009Co-Authors: Nicholas Kitchin, Joanna Southern, Rhonwen Morris, Ray Borrow, Anne Fiquet, Florence Boisnard, Stephane Thomas, Elizabeth MillerAbstract:Abstract This open-label, randomised, controlled study examined antibody persistence following infant vaccination at 2, 3 and 4 months of age with either an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Haemophilus influenzae type b (DT 5 aP-IPV-Hib; Pediacel ® ) or a whole-cell pertussis (DTwP//Hib + Oral Poliomyelitis Vaccine [OPV]) combination Vaccine, given concomitantly with meningococcal serogroup C conjugate (MCC) Vaccine, followed by a Hib booster at approximately 15 months of age. Immune responses were sustained to 3.5–4.5 years of age for all antigens contained in Pediacel. Administration of an acellular pertussis-containing quadrivalent pre-school booster (Td 5 ap-IPV; Repevax ® ), with or without measles, mumps and rubella (M-M-R™II) Vaccine, induced robust antibody responses indicative of protection, regardless of the Vaccine used for the primary series. Reactogenicity of Repevax was acceptable and consistent with previous experience.
-
a randomised controlled study of the reactogenicity of an acellular pertussis containing pentavalent infant Vaccine compared to a quadrivalent whole cell pertussis containing Vaccine and Oral Poliomyelitis Vaccine when given concurrently with meningococcal group c conjugate Vaccine to healthy uk infants at 2 3 and 4 months of age
Vaccine, 2006Co-Authors: Nicholas Kitchin, Joanna Southern, Rhonwen Morris, Fabienne Hemme, Keith Cartwright, Michael Watson, Elizabeth MillerAbstract:Two hundred forty-one healthy infants were enrolled in an open randomised controlled study of three doses of DTaP-IPV-Hib (Group 1) or DTwP/Hib+OPV (Group 2) at 2, 3 and 4 months of age given concurrently with a meningitis C conjugate Vaccine. After each dose, local reactions (any grade) were less common in Group 1 than Group 2 (p 37.5 degrees C, decreased feeding, reduced activity, irritability and crying in the week after vaccination were also less common in Group 1 than Group 2 (p<0.05 for each symptom, all doses combined). Severe local reactions and systemic symptoms were uncommon and occurred equally in both groups. The pentavalent DTaP-IPV-Hib Vaccine was less reactogenic than the quadrivalent DTwP-Hib Vaccine, as expected when changing from whole cell pertussis (wP) to an acellular pertussis (aP) component.
Luis Barreto - One of the best experts on this subject based on the ideXlab platform.
-
an evaluation of the safety and immunogenicity of a five component acellular pertussis diphtheria and tetanus toxoid Vaccine dtap when combined with a haemophilus influenzae type b tetanus toxoid conjugate Vaccine prp t in taiwanese infants
Pediatrics, 1999Co-Authors: Chinyun Lee, John Thipphawong, Limin Huang, Pinging Lee, Hsiuhui Chiu, Wendy Lin, Henri Debois, Dana Harrison, Fang Xie, Luis BarretoAbstract:OBJECTIVE Immunologic interference particular to the Haemophilus influenzae type b (Hib) response has been observed with previous acellular pertussis-Hib combination Vaccines. To test this hypothesis a clinical trial to assess the safety and immunogenicity of a five-component (pertussis toxoid [PT], filamentous hemagglutinin [FHA], pertactin [PRN], and fimbriae 2 and 3 [FIM]), pertussis Vaccine combined with diphtheria and tetanus toxoids (DTaP) when given simultaneously with a lyophilized Hib-tetanus toxoid conjugate Vaccine (PRP-T) in infants at 2, 4, 6, and 18 months of age was conducted. The study compared two methods of administration: both Vaccines combined in a single syringe and administered as a single injection, or both Vaccines administered concurrently but at separate sites of injection. METHODS Healthy 2-month-old infants were enrolled at the National Taiwan University Hospital. DTaP, PRP-T, and Oral Poliomyelitis Vaccine (OPV) were given at 2, 4, 6, and 18 months. Reaction information was collected by telephone 2 days after each vaccination. Serum was collected at 2, 6, 7, 18, and 19 months of age. RESULTS One hundred thirty-five healthy infants were enrolled in Taiwan, of which 127 (94%) completed the 18-month booster: 68 received the combined Vaccine and 67 the separate Vaccines. All Vaccines were well tolerated. No differences in rates of local and systemic reactions were seen between the two methods of administration. No serious adverse events were reported. Serologic responses were comparable between the groups. Pertussis responses (enzyme-liked immunoabsorbant assay units [EU]/mL) at 7 months were, for combined versus separate, PT (131 vs 105), FHA (116 vs 116), PRN (100 vs 77), and FIM (922 vs 702). At 19 months, pertussis results were, for combined versus separate, PT (216 vs 182), FHA (203 vs 200), PRN (263 vs 197), and FIM (892 vs 732). Only the 7-month PT response in the combined group was significantly higher (combined 131 EU/mL vs separate 105 EU/mL). After the third dose (age 6 months), all subjects achieved serologic serum antibody levels indicative of protection against Hib, diphtheria, tetanus, and poliovirus types 1, 2, and 3. In fact, 96% of children had anti-PRP levels indicative of protection (>/=0.15 microgram/mL) against Hib after only two doses. At 7 months, anti-PRP geometric mean titer values were 11.8 micrograms/mL in the combined group compared with 13.0 micrograms/mL in the separate group. The anti-PRP geometric mean titers after the 18-month booster were 58.5 micrograms/mL in the combined group versus 55.3 micrograms/mL in the separate group. CONCLUSION The five-component DTaP Vaccine may be combined with PRP-T Vaccine without clinically significant immunologic interaction when given in a 2-, 4-, 6-, and 18-month schedule.